Neogen Corporation (NEOG) — ESG & Values Scores

Environment story

Neogen has not disclosed Scope 1, 2, or 3 emissions data, renewable electricity percentages, or a net-zero target year in its 10-K filing. The company manufactures products containing rodent control chemicals (brodifacoum, bromethalin, diphacinone, zinc phosphide) and insect control products, creating potential environmental hazards. No material environmental controversies, toxic waste fines, or water pollution incidents are documented in available sources. The absence of disclosed climate metrics and net-zero commitments, combined with pesticide/rodenticide product lines, results in a below-average environmental score.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Cleaners & Disinfectants Divestiture

In April 2025, Neogen announced an agreement to sell its global Cleaners and Disinfectants business to Kersia Group for $130.0 million (closed July 18, 2025). This represents a strategic exit from a product category with inherent environmental compliance complexity.

Reduces direct manufacturing footprint and regulatory exposure but does not directly reduce operational emissions.

Social story

Neogen employs 2,974 people globally (1,676 in U.S., 1,298 international) as of May 31, 2025. The company reports 'good relations with both union and non-union employees' and has experienced no work stoppages. However, the 10-K does not disclose CEO-to-median-worker pay ratios, detailed workforce diversity percentages (gender/racial), executive-leadership diversity metrics, or supply-chain human-rights audits. The company states commitment to diversity and inclusion but provides no quantitative verification. Restructuring actions in fiscal 2025 (genomics business, $7.4M restructuring charges) reflect workforce management but lack transparent impact disclosure. No documented labor disputes, NLRB complaints, or union-suppression activities are evident in source materials.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Neogen DNA Workplace Culture Framework

Company has established Neogen DNA guiding workplace conduct, emphasizing Purpose & Promise, Principles, and Values (responsibility, consistency, integrity). Code of Conduct codifies ethical business conduct.

Establishes cultural framework but lacks quantified outcomes or third-party verification.
Employee Development and Talent Attraction

Programs include career planning, leadership development, performance management, and learning initiatives. Compensation and benefits designed to support physical/mental health, financial wellness, and family resources, varying by geography.

Demonstrates commitment to employee wellbeing but no metrics provided on participation rates or satisfaction.
Safety Culture and Injury Prevention

Zero-incident safety culture emphasis with injury prevention programs and cause investigation protocols. Management reports 'strong safety performance' but no OSHA recordable incident rates disclosed.

Safety commitment stated but lacks verifiable quantitative performance data.

Governance story

Neogen discloses material weaknesses in internal control over financial reporting in fiscal 2025. Specifically, the company identifies deficiencies in control activities across business and financial reporting processes, with particular weaknesses in management review controls supporting goodwill valuation assumptions. This contributed to a $1,059.3 million goodwill impairment charge in Food Safety segment. Board independence percentage is not disclosed in the 10-K; dual-class share structure is not mentioned (suggesting single-class common stock). Lobbying expenditures and PAC contributions are not disclosed. The company faces regulatory compliance risks related to export controls, tariffs, and trade sanctions, but no active antitrust, consumer-safety, or financial-fraud proceedings are described. The material control weaknesses and substantial goodwill impairment reduce governance confidence.

Criticisms on file

Material Weaknesses in Internal Control Over Financial Reporting
Source: Neogen 10-K Form, Item 9A Controls and Procedures; MD&A section
$1,059.3 Million Goodwill Impairment Charge (Food Safety Segment)
Source: Neogen 10-K Form, Consolidated Statement of Operations and MD&A; attributed to integration challenges with 3M Food Safety Division acquisition

Disclosed initiatives

Internal Control Remediation Efforts

Company has identified material weaknesses in control activities and is working to improve financial reporting controls. SAP ERP implementation (fiscal 2024 for U.S. food safety and Welsh facility) is part of ongoing control enhancement.

Remediation in process but material weaknesses remain unresolved as of filing date.
Code of Conduct and Ethics Framework

Company has formalized Code of Conduct codifying commitment to ethical business practices and has compliance systems addressing anti-bribery, anti-corruption, export controls, and data privacy.

Framework established but no independent audit or third-party certification disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Neogen Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Neogen Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)